Krystal Biotech, Inc. (KRYS) — Analyst outlook / Analyst consensus target is. Based on 17 analyst ratings, the consensus is bullish — 17 Buy.
The consensus price target is $311.00 (low: $224.00, high: $371.00), representing an upside of 15.2% from the current price $270.00.
Analysts estimate Earnings Per Share (EPS) of $2.76 and revenue of $0.29B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $3.12 vs est $2.76 (beat +13.2%). 2025: actual $7.08 vs est $6.78 (beat +4.5%). Analyst accuracy: 92%.
KRYS Stock — 12-Month Price Forecast
$311.00
▲ +15.19% Upside
Average Price Target
Based on 17 Wall Street analysts offering 12-month price targets for Krystal Biotech, Inc., the average price target is $311.00, with a high forecast of $371.00, and a low forecast of $224.00.
The average price target represents a +15.19% change from the last price of $270.00.
Highest Price Target
$371.00
Average Price Target
$311.00
Lowest Price Target
$224.00
KRYS Analyst Ratings
Buy
Based on 17 analysts giving stock ratings to Krystal Biotech, Inc. in the past 3 months
EPS Estimates — KRYS
92%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $3.12
vs Est $2.76
▲ 11.6% off
2025
Actual $7.08
vs Est $6.78
▲ 4.3% off
Profitability Outlook
Strong profitability with high earnings per share. EPS trend is improving.
Revenue Estimates — KRYS
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.291B
vs Est $0.290B
▲ 0.2% off
2025
Actual $0.389B
vs Est $0.388B
▲ 0.4% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
